{"gene":"PSMB9","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1994,"finding":"LMP2 (PSMB9) incorporation into 20S proteasomes alters peptidase activities: it reduces cleavage after acidic residues and increases hydrolysis after basic residues, without affecting hydrophobic activity. These changes are proportional to the amount of LMP2 incorporated and can account for the IFN-γ-induced shift in proteasome activity that favors generation of peptides with hydrophobic or basic C-termini for MHC class I presentation.","method":"Gene transfection of LMP2 into lymphoblasts or HeLa cells followed by in vitro peptidase activity assays on purified 20S and 26S proteasomes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with transfection, dose-response relationship established, replicated across cell types","pmids":["7937744"],"is_preprint":false},{"year":1994,"finding":"LMP2-deficient mice have proteasomes with altered peptidase activities and antigen-presenting cells show reduced capacity to stimulate a T cell hybridoma specific for an H-2Db-restricted influenza nucleoprotein epitope. LMP2-/- mice also have ~60-70% of wild-type CD8+ T lymphocyte levels and generate 5- to 6-fold fewer influenza nucleoprotein-specific CTL precursors, indicating LMP2 influences antigen processing in vivo.","method":"Gene targeting (LMP2 knockout mice), purified proteasome peptidase assays, T cell hybridoma stimulation assay, CTL precursor frequency measurement","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple orthogonal phenotypic readouts (biochemical + cellular + immunological), replicated in vivo","pmids":["7600282"],"is_preprint":false},{"year":1997,"finding":"Incorporation of MECL-1 into the 20S proteasome is directly dependent on LMP2 (PSMB9) expression but independent of LMP7. Conversely, LMP2 uptake into proteasomes is strongly enhanced by MECL-1 co-expression. LMP2 and MECL-1 are mutually required for incorporation at the level of proteasome precursor formation, ensuring concerted assembly of two IFN-γ-inducible subunits.","method":"Co-transfection experiments with LMP2 and MECL-1 expression constructs, analysis of proteasome subunit composition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct co-expression experiments with gain/loss of each partner, mechanistically well-defined, replicated with multiple combinations","pmids":["9256419"],"is_preprint":false},{"year":1994,"finding":"LMP2 (PSMB9) and LMP7 are synthesized as proproteins (~24 kDa and ~30 kDa respectively) and are processed within 13-16S proteasome precursor complexes; only their processed forms are incorporated into active 20S proteasomes.","method":"Pulse-chase experiments in mouse T cells, biochemical fractionation and analysis of 13-16S precursor complexes vs. mature 20S proteasomes","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with pulse-chase, direct demonstration of proprotein processing within precursor complexes","pmids":["8120905"],"is_preprint":false},{"year":1995,"finding":"LMP2+ proteasomes are specifically required for MHC class I-restricted presentation of influenza virus antigens. A T cell lymphoma (SP3) deficient only in LMP2 (among MHC-encoded antigen presentation genes) fails to present influenza antigens. Restoration of LMP2 expression (via IFN-γ transfection) rescues antigen presentation; antisense-LMP2 mRNA in IFN-γ-transfected SP3 cells or in LMP2-expressing L929 fibroblasts selectively represses presentation of the same antigens.","method":"Antisense RNA expression, IFN-γ gene transfection, CTL assays, analysis of selective LMP2 deficiency in SP3 lymphoma cells","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain- and loss-of-function with antisense in two cell lines, specific antigen presentation phenotype, selective LMP2 requirement established","pmids":["7583150"],"is_preprint":false},{"year":1995,"finding":"The PA28 (11S regulator) and LMP2/LMP7 subunits act together to govern peptide product profiles of 20S proteasomes in vitro. Incorporation of LMP2 and/or LMP7 changes cleavage site preference and peptide product quality from a 25-mer substrate. The 11S regulator does not preferentially activate LMP2- or LMP7-containing proteasomes but markedly changes both the quality and quantity of peptides produced when bound to any proteasome preparation.","method":"In vitro digestion of a 25-mer peptide substrate with purified 20S proteasomes from LMP transfectants ± purified PA28, product analysis by HPLC and electrospray mass spectrometry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro enzymatic assay with mass spectrometric product identification, multiple proteasome compositions tested","pmids":["7559557"],"is_preprint":false},{"year":1995,"finding":"Incorporation of LMP2 (alone or with LMP7) into 20S proteasomes changes subunit stoichiometry, alters cleavage site preference, and changes the quality of peptides processed from a murine cytomegalovirus IE pp89 25-mer polypeptide substrate, independent of IFN-γ. Both LMP subunits together also induce a drastic increase in positive cooperativity (Hill coefficient) between proteasome subunits.","method":"IFN-γ-independent LMP transfection into murine fibroblasts, in vitro dual-cleavage digestion assays with purified 20S proteasomes, fluorogenic peptide substrate assays (Vmax, S0.5, Hill coefficient)","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with multiple substrates and kinetic parameters measured","pmids":["7589133"],"is_preprint":false},{"year":1996,"finding":"LMP2 (PSMB9) and the constitutive subunit Y (delta) have opposing effects on proteasome peptidase activities: Y promotes cleavage after acidic residues while LMP2 suppresses it. Upon IFN-γ treatment, LMP2 replaces Y, thereby suppressing postacidic cleavage. Loss of Y by LMP2 incorporation accounts for suppression of postacidic cleavages, and loss of X contributes to increased hydrolysis after hydrophobic and basic residues.","method":"Transfection of X and Y subunit cDNAs into HeLa cells, peptidase activity assays, proteasome subunit composition analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assays with gain-of-function transfection, mechanistic subunit replacement model established","pmids":["8663318"],"is_preprint":false},{"year":1995,"finding":"The human TAP1 and LMP2 genes are divergently transcribed from a shared bidirectional promoter of only 593 bp. The NF-κB element proximal to the TAP1 gene controls TNF-α induction of both TAP1 and LMP2; an adjacent GC box is required for basal expression of both genes and augments TNF-α induction. In vivo footprinting confirmed protein-DNA interactions at these sites; in vitro binding confirmed p50/p65 and p52/p65 heterodimers bind the NF-κB site, and Sp1 binds the GC box.","method":"Bidirectional reporter assays, site-specific mutagenesis, in vivo genomic footprinting, in vitro DNA-binding studies","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — promoter mutagenesis, reporter assays, and in vivo/in vitro footprinting all converge on same regulatory elements","pmids":["7699330"],"is_preprint":false},{"year":1996,"finding":"IRF-1 is required for IFN-γ up-regulation of both TAP1 and LMP2. In vivo footprinting shows IFN-γ increases protein-DNA contacts at an IRF-E element essential for up-regulation of both genes; gel shift analysis shows this site binds IRF-1. In IRF-1-deficient mice, TAP1 and LMP2 expression are both greatly reduced, surface class I MHC is reduced, and CD8+ T cells are reduced.","method":"In vivo footprinting, gel shift (EMSA), analysis of IRF-1-/- mice (KO phenotype), surface MHC and CD8 T cell measurement","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with multiple cellular phenotypes, confirmed by molecular footprinting and EMSA","pmids":["8885869"],"is_preprint":false},{"year":2000,"finding":"Adenovirus E1A down-regulates LMP2 transcription by binding to Stat1 and interfering with the formation of the constitutive Stat1-IRF1 complex that normally occupies the overlapping ICS-2/GAS element of the LMP2 promoter. E1A sequesters IRF1 by occupying IRF1-binding domains on Stat1. The mutant E1A protein RG2 (binds Stat1 but not CBP/p300) also represses LMP2, while Delta2-36 (binds neither) does not, establishing that Stat1-binding is the key mechanism.","method":"E1A mutant analysis, EMSA/gel shift showing Stat1-IRF1 complex formation, reporter assays, protein-protein interaction studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — structure-function mutagenesis of E1A, EMSA for complex disruption, mechanistic dissection with multiple E1A mutants","pmids":["10764778"],"is_preprint":false},{"year":1993,"finding":"LMP2 (PSMB9) is synthesized as a proprotein of 24 kDa; pulse-chase experiments demonstrate that the LMP2 polypeptide undergoes post-translational processing (from ~22.3 kDa to ~21.5 kDa) when incorporated into proteasomes. Two mRNA forms exist (LMP2.1 and LMP2.s resulting from alternative splicing of 30 bp from the first exon), yet both encode proteins processed to the same final size in proteasomes.","method":"Pulse-chase experiments, immunoblot with anti-recombinant LMP2.s antibodies, RT-PCR/cDNA sequence analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pulse-chase biochemistry plus sequence analysis, single lab","pmids":["7829535"],"is_preprint":false},{"year":2000,"finding":"Overexpression of all three immunoproteasome subunits (LMP2, LMP7, and MECL-1) together markedly enhances MHC class I presentation of the immunodominant LCMV NP118 epitope. In vitro, immunoproteasomes generate higher amounts of 11- and 12-mer precursor fragments containing NP118, consistent with cytosolic precursor generation for TAP transport. PA28 overexpression does not have a comparable effect on this epitope.","method":"Triple transfection of LMP2/LMP7/MECL-1, CTL presentation assays, in vitro digestion of substrate with HPLC product analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with defined substrates and product identification combined with cell-based presentation assays","pmids":["10878350"],"is_preprint":false},{"year":2006,"finding":"LMP2-/- mice have reduced proteasome activities (chymotryptic, tryptic, and caspase-like) in both brain and liver, accompanied by increased levels of oxidatively damaged proteins in both tissues. This demonstrates that individual proteasome subunit (LMP2) expression regulates overall proteasome activity and protein oxidation in vivo.","method":"LMP2 knockout mice, proteasome activity assays (fluorogenic substrates), protein oxidation measurement (carbonyl content) in brain and liver tissue","journal":"Antioxidants & redox signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with biochemical readout in two tissues, single lab","pmids":["16487046"],"is_preprint":false},{"year":2006,"finding":"HIV-1 Tat protein represses LMP2 transcription by competing with STAT1 for binding to IRF-1 on the overlapping ICS-2/GAS element of the LMP2 promoter. The constitutive LMP2 basal transcription depends on an unphosphorylated STAT1-IRF-1 complex at this element; intracellular Tat sequesters IRF-1, impairing complex formation and reducing LMP2 expression, with a consequent increase in proteolytic activity.","method":"Reporter assays, EMSA/ChIP to demonstrate STAT1-IRF-1 complex disruption by Tat, Western blot for LMP2 protein levels, proteasome activity assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA for molecular mechanism combined with functional reporter and activity assays, single lab","pmids":["16512786"],"is_preprint":false},{"year":2014,"finding":"IFN-γ controls IL-33 protein levels through STAT1 and the LMP2 proteasome subunit. IFN-γ elevates LMP2 levels; siRNA-mediated silencing of LMP2 abrogates the IFN-γ-induced down-regulation of IL-33 protein, indicating LMP2 mediates non-canonical (non-antigen presentation) proteolysis of IL-33 in a caspase-independent fashion in pulmonary fibroblasts.","method":"siRNA knockdown of LMP2 and STAT1, pharmacological inhibition, adenoviral dual gene delivery, Western blot for IL-33 protein levels in vitro and in vivo","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with rescue experiments, in vivo confirmation, single lab","pmids":["24619410"],"is_preprint":false},{"year":2006,"finding":"LMP2 siRNA knockdown in the human invasive extravillous trophoblast cell line (HTR8/Svneo) suppresses MMP-2 and MMP-9 mRNA expression and activities. LMP2 contributes to IκBα degradation and p50 NF-κB subunit generation; inhibition of LMP2 reduces nuclear translocation of active NF-κB heterodimers, thereby reducing MMP-2 and MMP-9 expression.","method":"siRNA transfection, RT-PCR for MMP-2/9, gelatin zymography for MMP activity, Western blot for IκBα, p50, p65 in cytosolic and nuclear fractions, NF-κB inhibitor (SN50) control","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with multiple orthogonal readouts (mRNA, activity, protein fractionation), single lab","pmids":["16222703"],"is_preprint":false},{"year":2010,"finding":"LMP2-/- mice have mixed (hybrid) proteasomes in immune cells containing both standard and immunosubunits, and this compromises antiviral antibody responses, splenic B cell numbers, adoptively transferred B cell survival and function, Th cell function, and dendritic cell secretion of IL-6, TNF-α, IL-1β, and type I IFNs. These defects are associated with altered NF-κB activity rather than compromised overall protein degradation.","method":"LMP2 knockout mice, adoptive transfer experiments, cytokine measurements by ELISA, NF-κB activity assays, flow cytometry for immune cell populations","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with multiple immune readouts and mechanistic linkage to NF-κB, single lab","pmids":["20228196"],"is_preprint":false},{"year":2018,"finding":"Co-inhibition of LMP2 (β1i/PSMB9) and LMP7 (β5i) is required to block autoimmunity. Selective LMP7-only inhibition with PRN1126 has limited effects on IL-6 secretion, experimental colitis, and EAE. Prolonged ONX 0914 exposure inhibits both LMP7 and LMP2. Combined LMP7+LMP2 inhibition impairs MHC class I surface expression, IL-6 secretion, Th17 differentiation, and strongly ameliorates disease in colitis and EAE models.","method":"Selective inhibitors (PRN1126, LU-001i, ML604440, ONX 0914), cytokine assays (IL-6), flow cytometry for MHC I and Th17 cells, in vivo colitis and EAE models","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with selective inhibitors in vitro and in vivo, multiple disease models, single lab","pmids":["30279279"],"is_preprint":false},{"year":2021,"finding":"A de novo PSMB9 p.G156D mutation causes a novel type I interferonopathy. Patient-derived B lymphoblastoid cell lines show reduced proteasome activities; exogenous transduction of mutant PSMB9 p.G156D into normal LCLs significantly suppresses proteasome activities and eliminates endogenous PSMB9 protein along with reduction of other immunoproteasome subunits PSMB8 and PSMB10, demonstrating a dominant-negative mechanism with co-subunit destabilization.","method":"Whole-exome sequencing, patient-derived LCL proteasome activity assays, lentiviral transduction of mutant PSMB9 into normal LCLs, Western blot for immunoproteasome subunit levels","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient mutation validated by transduction into normal cells with biochemical readout, single lab","pmids":["33727065"],"is_preprint":false},{"year":2023,"finding":"In human cells, mitochondrial dysfunction leads to upregulation of the immunoproteasome-specific subunit PSMB9 as a proteostasis defense response. PSMB9 expression under mitochondrial stress is dependent on the translation elongation factor EEF1A2. This defines a mode of proteasomal activation through change in proteasome composition driven by EEF1A2 and its spatial regulation.","method":"Mitochondrial dysfunction models in human cells, proteomics, siRNA knockdown of EEF1A2, Western blot for PSMB9 and other proteasome subunits, proteasome activity assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-method study (proteomics, siRNA, activity assays) in human cells, single lab","pmids":["37433777"],"is_preprint":false},{"year":2021,"finding":"LMP2 (PSMB9) inhibition ameliorates ischemia/hypoxia-induced blood-brain barrier injury through activation of the Wnt/β-catenin signaling pathway. LMP2 knockdown in rat MCAO/reperfusion model restores tight junction proteins (occludin, claudin-1, ZO-1), increases microvascular density, and decreases BBB permeability. Co-silencing of β-catenin partially counteracted benefits of LMP2 silencing, establishing LMP2's pathway position upstream of Wnt/β-catenin.","method":"Lentivirus-mediated LMP2 shRNA in MCAO/R rat model, siRNA in OGD/R cell model, co-transfection with β-catenin siRNA, Western blot, Evans blue permeability assay, immunofluorescence","journal":"Military Medical Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo shRNA + in vitro siRNA with epistasis (β-catenin co-KD), multiple orthogonal readouts, single lab","pmids":["34857032"],"is_preprint":false},{"year":2006,"finding":"PSMB9 (LMP2) knockdown in keratinocytes leads to significant suppression of TGF-β2 and TGF-β3, which are inducers of versican synthesis. IFN-γ stimulates PSMB9 expression in cultured keratinocytes. This places PSMB9 upstream of TGF-β2/β3 in the pathway regulating versican-mediated extracellular matrix composition in skin.","method":"siRNA knockdown of PSMB9 in keratinocytes, RT-PCR/Western blot for TGF-β2, TGF-β3, versican; IFN stimulation assays; proteomics of DM vs. healthy skin","journal":"The British journal of dermatology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — siRNA KD with mRNA readout, single method for the mechanistic claim, single lab","pmids":["26713607"],"is_preprint":false},{"year":2014,"finding":"Structure-based design identified β1i (PSMB9/LMP2)-selective inhibitors using X-ray structures of murine constitutive and immunoproteasome 20S core particles as templates. Cell-permeable compounds with selectivity for β1i over β5i and over constitutive β1c were developed, confirming that the PSMB9 active site has structural features distinct from other proteasome catalytic subunits.","method":"Structure-based drug design using X-ray crystal structures of 20S proteasome, synthesis and biochemical testing of inhibitors for selectivity and potency against individual subunits","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — structure-guided design validated by biochemical selectivity assays; structural data from murine not human proteasome","pmids":["25006746"],"is_preprint":false},{"year":2007,"finding":"LMP2-specific irreversible small molecule inhibitors selectively modify the LMP2/β1i subunit of the immunoproteasome with high specificity. LMP2-rich cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor compared to LMP2-deficient cancer cells, implicating LMP2 catalytic activity in regulating cell growth of tumors that highly express it.","method":"Activity-based labeling with LMP2-selective inhibitors, cell viability assays comparing LMP2-expressing vs. LMP2-deficient cancer cell lines","journal":"Chemistry & biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — activity-based chemical probe with selectivity demonstrated, functional growth assay comparing isogenic LMP2+/- cells, single lab","pmids":["17462577"],"is_preprint":false},{"year":2006,"finding":"Heat shock transcriptionally up-regulates lmp2 and lmp7 in mouse and human cells, and heat-shocked cells show enhanced presentation of immunoproteasome-dependent MHC class I epitopes (LCMV NP118-126, adenovirus E1B192-200) but not immunoproteasome-independent epitopes, demonstrating that heat shock-driven LMP2 induction functionally alters antigen processing.","method":"RT-PCR for lmp2/lmp7 mRNA after heat shock, CTL presentation assays for immunoproteasome-dependent vs. -independent epitopes","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional induction linked to functional presentation change with epitope-specificity controls, single lab","pmids":["17142736"],"is_preprint":false},{"year":1997,"finding":"In the NOD mouse, a T→A mutation in the shared bidirectional promoter of Lmp2 and Tap1 eliminates an initiator (Inr) element in the Lmp2 orientation, reduces Lmp2 and Tap1 mRNA levels, eliminates a Lmp2 transcription start site, and reduces proteasome peptide substrate activity. This promoter mutation thus reduces both Lmp2 and Tap1 gene expression.","method":"Sequencing of NOD vs. Balb/c promoter, Northern blot, 5'-RACE, luciferase reporter assays with NOD promoter construct, proteasome activity assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutation identified and functionally confirmed by reporter and activity assays, multiple methods, single lab","pmids":["9300732"],"is_preprint":false}],"current_model":"PSMB9 (LMP2/β1i) is an IFN-γ-inducible catalytic beta subunit of the immunoproteasome that is synthesized as a proprotein, processed within 13-16S precursor complexes, and incorporated into 20S proteasomes where it replaces the constitutive delta/Y subunit; its incorporation suppresses cleavage after acidic residues and enhances cleavage after basic residues, shifting peptide product profiles toward ligands suitable for MHC class I loading, and requires mutual co-incorporation with MECL-1; LMP2 expression is coordinately regulated with TAP1 from a shared bidirectional promoter via IRF-1, STAT1, NF-κB and Sp1, and is subject to repression by viral proteins (adenovirus E1A, HIV-1 Tat) that disrupt the constitutive STAT1-IRF-1 complex; beyond antigen presentation, LMP2 regulates NF-κB-dependent gene expression (including MMP-2/9), controls IL-33 proteolysis, influences Wnt/β-catenin signaling in endothelial cells under ischemia, and is induced during mitochondrial stress in an EEF1A2-dependent manner to preserve proteostasis."},"narrative":{"mechanistic_narrative":"PSMB9 (LMP2/β1i) is an IFN-γ-inducible catalytic β subunit of the immunoproteasome that reshapes proteasomal peptide output to favor MHC class I antigen presentation [PMID:7937744, PMID:7583150]. Synthesized as a ~24 kDa proprotein, it is processed within 13-16S precursor complexes and only the mature form is incorporated into 20S proteasomes [PMID:8120905, PMID:7829535]. Upon incorporation it replaces the constitutive Y/δ subunit, suppressing cleavage after acidic residues while enhancing hydrolysis after basic residues in a dose-dependent manner; these opposing activities of Y and LMP2 account for the IFN-γ-induced shift in proteasome specificity [PMID:7937744, PMID:8663318]. Its assembly into the 20S particle is mutually co-dependent with MECL-1, ensuring concerted incorporation of two immunosubunits at the precursor stage [PMID:9256419]. Functionally, LMP2-containing proteasomes are selectively required to generate cytosolic precursor fragments for defined viral epitopes, and LMP2-deficient mice show reduced CD8+ T cell numbers and impaired CTL generation against influenza nucleoprotein [PMID:7600282, PMID:7583150, PMID:10878350]. PSMB9 expression is coordinately regulated with TAP1 from a shared 593 bp bidirectional promoter, driven by IRF-1, a constitutive STAT1-IRF-1 complex, NF-κB (p50/p65), and Sp1, and is repressed by viral proteins (adenovirus E1A, HIV-1 Tat) that disrupt the STAT1-IRF-1 complex at the overlapping ICS-2/GAS element [PMID:7699330, PMID:8885869, PMID:10764778, PMID:16512786]. Beyond antigen processing, PSMB9 supports broader proteostasis, controlling overall proteasome activity and limiting protein oxidation in vivo [PMID:16487046], modulating NF-κB-dependent gene expression including MMP-2/9 [PMID:16222703], mediating non-canonical IL-33 proteolysis [PMID:24619410], and being induced as a proteostasis defense during mitochondrial stress in an EEF1A2-dependent manner [PMID:37433777]. A de novo PSMB9 p.G156D mutation causes a type I interferonopathy through a dominant-negative mechanism that destabilizes co-subunits PSMB8 and PSMB10 [PMID:33727065].","teleology":[{"year":1994,"claim":"Established that LMP2 is a catalytic immunoproteasome subunit whose incorporation directly rewires proteasome cleavage specificity toward MHC class I-suitable peptides, rather than being merely a passive structural component.","evidence":"LMP2 transfection into lymphoblasts/HeLa cells with in vitro peptidase assays on purified 20S/26S proteasomes","pmids":["7937744"],"confidence":"High","gaps":["Did not establish the in vivo consequence for antigen presentation","Did not resolve the structural basis of the cleavage shift"]},{"year":1993,"claim":"Showed that LMP2 is made as a 24 kDa proprotein and post-translationally processed during proteasome incorporation, defining a maturation requirement for catalytic activity.","evidence":"Pulse-chase and immunoblot in mouse T cells with cDNA/splice-form analysis","pmids":["7829535"],"confidence":"Medium","gaps":["Did not identify the processing protease","Functional role of the two splice forms unresolved"]},{"year":1994,"claim":"Defined where processing occurs by showing LMP2 propeptide maturation happens within 13-16S precursor complexes and only mature forms enter active 20S particles.","evidence":"Pulse-chase and biochemical fractionation of precursor vs. mature complexes in mouse T cells","pmids":["8120905"],"confidence":"High","gaps":["Assembly chaperones not identified","Order of subunit recruitment within precursors not fully resolved"]},{"year":1994,"claim":"Linked LMP2 biochemistry to immune function in vivo, demonstrating that LMP2 loss alters proteasome activity and reduces CD8+ T cell numbers and antigen-specific CTL precursor generation.","evidence":"LMP2 knockout mice with proteasome assays, T cell hybridoma stimulation, and CTL precursor frequency","pmids":["7600282"],"confidence":"High","gaps":["Did not separate effects on proteasome activity from effects on T cell development","Specific epitope dependence not yet mapped"]},{"year":1995,"claim":"Confirmed selective LMP2 dependence of antigen presentation using gain- and loss-of-function in cells, showing LMP2 is specifically required for presentation of defined viral antigens.","evidence":"Antisense LMP2 RNA, IFN-γ transfection, and CTL assays in SP3 lymphoma and L929 fibroblasts","pmids":["7583150"],"confidence":"High","gaps":["Generality across diverse epitopes not established","Did not address contribution of other immunosubunits"]},{"year":1995,"claim":"Resolved how LMP2 cooperates with regulators and other subunits, showing LMP2/LMP7 set cleavage-site preference while PA28/11S independently boosts peptide quality and quantity.","evidence":"In vitro digestion of 25-mer substrates with purified LMP-transfectant 20S ± PA28, HPLC/MS product analysis; IFN-γ-independent transfection with kinetic measurements","pmids":["7559557","7589133"],"confidence":"High","gaps":["Substrate-specificity rules for endogenous antigens not generalized","Cooperativity mechanism between subunits not structurally defined"]},{"year":1996,"claim":"Pinpointed the molecular basis of the cleavage shift to subunit replacement, showing LMP2 and constitutive Y have opposing effects and LMP2 substitution suppresses postacidic cleavage.","evidence":"Transfection of X/Y subunit cDNAs into HeLa cells with peptidase and composition analyses","pmids":["8663318"],"confidence":"High","gaps":["Atomic basis of substrate specificity difference not resolved","Contribution of X loss not fully separated from Y loss"]},{"year":1997,"claim":"Established a co-assembly rule whereby LMP2 and MECL-1 are mutually required for incorporation at the precursor stage, independent of LMP7.","evidence":"Co-transfection of LMP2 and MECL-1 with proteasome subunit composition analysis","pmids":["9256419"],"confidence":"High","gaps":["Molecular signal coordinating their co-incorporation not identified","Stoichiometry of mixed/hybrid proteasomes not addressed"]},{"year":1995,"claim":"Defined the transcriptional architecture of PSMB9, showing TAP1 and LMP2 share a compact bidirectional promoter with NF-κB-driven cytokine induction and an Sp1/GC box for basal expression.","evidence":"Bidirectional reporters, mutagenesis, in vivo footprinting, and in vitro NF-κB/Sp1 DNA-binding studies","pmids":["7699330"],"confidence":"High","gaps":["Did not address IFN-γ-specific elements","Cell-type-specific regulation not explored"]},{"year":1996,"claim":"Identified IRF-1 as the IFN-γ-responsive transcription factor required for coordinate TAP1/LMP2 upregulation, linking promoter occupancy to MHC class I surface expression and CD8+ T cell numbers.","evidence":"In vivo footprinting, EMSA, and IRF-1-deficient mice with MHC and CD8 readouts","pmids":["8885869"],"confidence":"High","gaps":["Interplay with STAT1 at the same element not yet dissected","Did not separate direct vs. indirect IRF-1 effects"]},{"year":1997,"claim":"Connected promoter variation to disease susceptibility, showing a NOD-mouse promoter mutation ablates an Inr element and reduces both Lmp2 and Tap1 expression and proteasome activity.","evidence":"Sequencing, Northern blot, 5'-RACE, luciferase reporters, and proteasome activity assays of NOD vs. control promoters","pmids":["9300732"],"confidence":"Medium","gaps":["Causal link to autoimmune phenotype not directly demonstrated","Effect specific to mouse strain context"]},{"year":2000,"claim":"Showed viral subversion of PSMB9 by demonstrating adenovirus E1A represses LMP2 transcription by sequestering IRF1 via STAT1 binding, disrupting the constitutive STAT1-IRF1 complex.","evidence":"E1A structure-function mutants, EMSA for complex disruption, and reporter assays","pmids":["10764778"],"confidence":"High","gaps":["Did not quantify downstream impact on antigen presentation in infected cells","Other viral repressors not addressed"]},{"year":2000,"claim":"Demonstrated combinatorial enhancement of presentation, showing co-overexpression of LMP2/LMP7/MECL-1 markedly boosts presentation of an immunodominant epitope by generating more cytosolic precursor fragments.","evidence":"Triple transfection with CTL assays and in vitro substrate digestion/HPLC analysis","pmids":["10878350"],"confidence":"High","gaps":["Relative contribution of each subunit not separated","Did not generalize beyond the tested epitope"]},{"year":2006,"claim":"Extended PSMB9 function to global proteostasis, showing LMP2 loss reduces multiple proteasome activities and increases oxidative protein damage in non-immune tissues.","evidence":"LMP2 knockout mice with fluorogenic activity assays and protein carbonyl measurements in brain and liver","pmids":["16487046"],"confidence":"Medium","gaps":["Mechanism linking subunit loss to global activity not defined","Single lab"]},{"year":2006,"claim":"Defined an HIV-1 strategy paralleling E1A, with Tat repressing LMP2 by competing with STAT1 for IRF-1 at the ICS-2/GAS element.","evidence":"Reporter assays, EMSA/ChIP for STAT1-IRF-1 disruption, and proteasome activity assays","pmids":["16512786"],"confidence":"Medium","gaps":["Functional impact on viral antigen presentation not quantified","Single lab"]},{"year":2006,"claim":"Implicated PSMB9 in NF-κB-driven matrix remodeling, showing LMP2 knockdown reduces IκBα degradation, p50 generation, and MMP-2/9 expression in trophoblasts.","evidence":"siRNA with RT-PCR, gelatin zymography, and cytosolic/nuclear fractionation Western blots","pmids":["16222703"],"confidence":"Medium","gaps":["Direct substrate of LMP2 in NF-κB activation not identified","Single cell type"]},{"year":2006,"claim":"Linked stress-induced LMP2 to functional changes in antigen processing, showing heat shock transcriptionally upregulates lmp2/lmp7 and selectively enhances immunoproteasome-dependent epitope presentation.","evidence":"RT-PCR after heat shock and CTL assays with dependent vs. independent epitope controls","pmids":["17142736"],"confidence":"Medium","gaps":["Transcription factors mediating heat-shock induction not identified","Single lab"]},{"year":2007,"claim":"Provided chemical-biology evidence that LMP2 catalytic activity has cell-intrinsic roles, with LMP2-selective irreversible inhibitors preferentially inhibiting growth of LMP2-rich cancer cells.","evidence":"Activity-based labeling with LMP2-selective probes and viability assays in LMP2+/- cancer lines","pmids":["17462577"],"confidence":"Medium","gaps":["Substrates mediating growth effect unknown","Single lab"]},{"year":2010,"claim":"Refined the LMP2 phenotype mechanistically, showing immune defects in LMP2-/- mice track with altered NF-κB activity rather than impaired bulk protein degradation.","evidence":"LMP2 knockout mice with adoptive transfer, cytokine ELISAs, NF-κB activity assays, and flow cytometry","pmids":["20228196"],"confidence":"Medium","gaps":["Direct NF-κB substrate of immunoproteasome not identified","Single lab"]},{"year":2014,"claim":"Identified a non-antigen-presentation proteolytic role, showing IFN-γ downregulates IL-33 protein through STAT1 and LMP2 in a caspase-independent manner.","evidence":"siRNA knockdown of LMP2/STAT1, adenoviral delivery, and Western blot for IL-33 in vitro and in vivo","pmids":["24619410"],"confidence":"Medium","gaps":["Direct vs. indirect cleavage of IL-33 not established","Single lab"]},{"year":2014,"claim":"Confirmed PSMB9 has a structurally distinct active site by designing β1i-selective inhibitors using immunoproteasome crystal structures.","evidence":"Structure-based drug design from murine 20S X-ray structures with biochemical selectivity assays","pmids":["25006746"],"confidence":"Medium","gaps":["Structural data from murine, not human, proteasome","Selectivity in cellular context not fully validated"]},{"year":2018,"claim":"Established that dual LMP2+LMP7 inhibition is required for therapeutic immunomodulation, showing LMP7-only blockade is insufficient to suppress autoimmunity.","evidence":"Selective inhibitors with IL-6 assays, MHC I and Th17 flow cytometry, and colitis/EAE models","pmids":["30279279"],"confidence":"Medium","gaps":["Relative catalytic contribution of LMP2 vs. LMP7 not quantified","Single lab"]},{"year":2021,"claim":"Demonstrated PSMB9 causes human Mendelian disease, identifying a de novo p.G156D mutation that drives a type I interferonopathy through a dominant-negative mechanism destabilizing co-subunits.","evidence":"Whole-exome sequencing, patient LCL activity assays, and lentiviral transduction of mutant PSMB9 into normal LCLs with subunit Westerns","pmids":["33727065"],"confidence":"Medium","gaps":["Mechanism linking proteasome dysfunction to interferon activation not defined","Single patient/lab"]},{"year":2021,"claim":"Placed PSMB9 upstream of Wnt/β-catenin signaling in vascular pathology, showing LMP2 inhibition restores blood-brain barrier integrity after ischemia in a β-catenin-dependent manner.","evidence":"Lentiviral LMP2 shRNA in MCAO/R rats, OGD/R cell models, β-catenin co-silencing epistasis, and permeability/tight-junction readouts","pmids":["34857032"],"confidence":"Medium","gaps":["Mechanism connecting LMP2 to Wnt/β-catenin not molecularly defined","Single lab"]},{"year":2023,"claim":"Revealed a mitochondrial-stress proteostasis role, showing PSMB9 is upregulated as a defense response in an EEF1A2-dependent manner under mitochondrial dysfunction.","evidence":"Mitochondrial dysfunction models in human cells with proteomics, EEF1A2 siRNA, and proteasome activity assays","pmids":["37433777"],"confidence":"Medium","gaps":["Mechanism of EEF1A2-dependent PSMB9 induction not defined","Single lab"]},{"year":null,"claim":"How non-antigen-presentation roles of PSMB9 (NF-κB regulation, IL-33 and IL-33-like substrate proteolysis, Wnt/β-catenin and mitochondrial-stress signaling) are mechanistically connected to its catalytic specificity remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Direct physiological substrates beyond MHC-precursor peptides not identified","Human structural model of the PSMB9 active site not established","Mechanism linking proteasome dysfunction to interferon hyperactivation unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,5,6,7,15]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,7,13]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[2,3]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,4,12,17]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,3,13,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,9,10,14]}],"complexes":["immunoproteasome 20S core particle","13-16S proteasome precursor complex"],"partners":["MECL-1","PSMB8","PSMB10","TAP1","IRF1","STAT1","EEF1A2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28065","full_name":"Proteasome subunit beta type-9","aliases":["Low molecular mass protein 2","Macropain chain 7","Multicatalytic endopeptidase complex chain 7","Proteasome chain 7","Proteasome subunit beta-1i","Really interesting new gene 12 protein"],"length_aa":219,"mass_kda":23.3,"function":"The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH (PubMed:33727065, PubMed:34819510). The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB6 by PSMB9 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P28065/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PSMB9","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PSMB9","total_profiled":1310},"omim":[{"mim_id":"620796","title":"PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 6; PRAAS6","url":"https://www.omim.org/entry/620796"},{"mim_id":"617591","title":"PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 3; PRAAS3","url":"https://www.omim.org/entry/617591"},{"mim_id":"613537","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 5; NLRC5","url":"https://www.omim.org/entry/613537"},{"mim_id":"613386","title":"PROTEASOME MATURATION PROTEIN; POMP","url":"https://www.omim.org/entry/613386"},{"mim_id":"611137","title":"PROTEASOME SUBUNIT, BETA-TYPE, 11; PSMB11","url":"https://www.omim.org/entry/611137"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":140.3}],"url":"https://www.proteinatlas.org/search/PSMB9"},"hgnc":{"alias_symbol":["RING12","beta1i","PSMB6i"],"prev_symbol":["LMP2"]},"alphafold":{"accession":"P28065","domains":[{"cath_id":"3.60.20.10","chopping":"17-207","consensus_level":"high","plddt":94.976,"start":17,"end":207}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28065","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28065-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28065-F1-predicted_aligned_error_v6.png","plddt_mean":90.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PSMB9","jax_strain_url":"https://www.jax.org/strain/search?query=PSMB9"},"sequence":{"accession":"P28065","fasta_url":"https://rest.uniprot.org/uniprotkb/P28065.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28065/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28065"}},"corpus_meta":[{"pmid":"1313894","id":"PMC_1313894","title":"Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.","date":"1992","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1313894","citation_count":428,"is_preprint":false},{"pmid":"7600282","id":"PMC_7600282","title":"Altered peptidase and viral-specific T cell response in LMP2 mutant mice.","date":"1994","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7600282","citation_count":364,"is_preprint":false},{"pmid":"7937744","id":"PMC_7937744","title":"Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7937744","citation_count":277,"is_preprint":false},{"pmid":"22249143","id":"PMC_22249143","title":"The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC).","date":"2012","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/22249143","citation_count":265,"is_preprint":false},{"pmid":"8290598","id":"PMC_8290598","title":"An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8290598","citation_count":212,"is_preprint":false},{"pmid":"7699330","id":"PMC_7699330","title":"Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7699330","citation_count":208,"is_preprint":false},{"pmid":"7559557","id":"PMC_7559557","title":"The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7559557","citation_count":202,"is_preprint":false},{"pmid":"16298241","id":"PMC_16298241","title":"Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains.","date":"2006","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/16298241","citation_count":178,"is_preprint":false},{"pmid":"9256419","id":"PMC_9256419","title":"The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9256419","citation_count":171,"is_preprint":false},{"pmid":"1313931","id":"PMC_1313931","title":"Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma.","date":"1992","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1313931","citation_count":158,"is_preprint":false},{"pmid":"7693972","id":"PMC_7693972","title":"HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.","date":"1993","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/7693972","citation_count":149,"is_preprint":false},{"pmid":"2157888","id":"PMC_2157888","title":"A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.","date":"1990","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/2157888","citation_count":144,"is_preprint":false},{"pmid":"7589133","id":"PMC_7589133","title":"Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7589133","citation_count":141,"is_preprint":false},{"pmid":"8120905","id":"PMC_8120905","title":"20 S proteasomes are assembled via distinct precursor complexes. Processing of LMP2 and LMP7 proproteins takes place in 13-16 S preproteasome complexes.","date":"1994","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8120905","citation_count":129,"is_preprint":false},{"pmid":"11039910","id":"PMC_11039910","title":"Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11039910","citation_count":127,"is_preprint":false},{"pmid":"8663318","id":"PMC_8663318","title":"Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663318","citation_count":126,"is_preprint":false},{"pmid":"8885869","id":"PMC_8885869","title":"Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1-/- mice.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8885869","citation_count":123,"is_preprint":false},{"pmid":"9746788","id":"PMC_9746788","title":"Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9746788","citation_count":118,"is_preprint":false},{"pmid":"21821548","id":"PMC_21821548","title":"A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.","date":"2011","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21821548","citation_count":117,"is_preprint":false},{"pmid":"8383224","id":"PMC_8383224","title":"The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro.","date":"1993","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8383224","citation_count":103,"is_preprint":false},{"pmid":"10878350","id":"PMC_10878350","title":"Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10878350","citation_count":96,"is_preprint":false},{"pmid":"17462577","id":"PMC_17462577","title":"LMP2-specific inhibitors: chemical genetic tools for proteasome biology.","date":"2007","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/17462577","citation_count":95,"is_preprint":false},{"pmid":"7847389","id":"PMC_7847389","title":"Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7847389","citation_count":91,"is_preprint":false},{"pmid":"7583150","id":"PMC_7583150","title":"LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes.","date":"1995","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/7583150","citation_count":88,"is_preprint":false},{"pmid":"10818681","id":"PMC_10818681","title":"Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?","date":"2000","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10818681","citation_count":87,"is_preprint":false},{"pmid":"20228196","id":"PMC_20228196","title":"Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20228196","citation_count":87,"is_preprint":false},{"pmid":"34857032","id":"PMC_34857032","title":"Inhibition of the immunoproteasome LMP2 ameliorates ischemia/hypoxia-induced blood-brain barrier injury through the Wnt/β-catenin signalling pathway.","date":"2021","source":"Military Medical Research","url":"https://pubmed.ncbi.nlm.nih.gov/34857032","citation_count":84,"is_preprint":false},{"pmid":"25006746","id":"PMC_25006746","title":"Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25006746","citation_count":83,"is_preprint":false},{"pmid":"15235393","id":"PMC_15235393","title":"The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.","date":"2004","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/15235393","citation_count":81,"is_preprint":false},{"pmid":"8301122","id":"PMC_8301122","title":"MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8301122","citation_count":80,"is_preprint":false},{"pmid":"14679129","id":"PMC_14679129","title":"Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.","date":"2004","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14679129","citation_count":78,"is_preprint":false},{"pmid":"7907993","id":"PMC_7907993","title":"PRE3, highly homologous to the human major histocompatibility complex-linked LMP2 (RING12) gene, codes for a yeast proteasome subunit necessary for the peptidylglutamyl-peptide hydrolyzing activity.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7907993","citation_count":76,"is_preprint":false},{"pmid":"11059775","id":"PMC_11059775","title":"Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11059775","citation_count":71,"is_preprint":false},{"pmid":"26428374","id":"PMC_26428374","title":"Latent Membrane Protein 2 (LMP2).","date":"2015","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26428374","citation_count":68,"is_preprint":false},{"pmid":"30279279","id":"PMC_30279279","title":"Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/30279279","citation_count":68,"is_preprint":false},{"pmid":"17590084","id":"PMC_17590084","title":"Cis- and trans-acting elements regulate the mouse Psmb9 meiotic recombination hotspot.","date":"2007","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17590084","citation_count":66,"is_preprint":false},{"pmid":"22677907","id":"PMC_22677907","title":"A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice.","date":"2012","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22677907","citation_count":64,"is_preprint":false},{"pmid":"9815722","id":"PMC_9815722","title":"IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma.","date":"1997","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9815722","citation_count":62,"is_preprint":false},{"pmid":"8365398","id":"PMC_8365398","title":"The major-histocompatibility-complex-encoded beta-type proteasome subunits LMP2 and LMP7. Evidence that LMP2 and LMP7 are synthesized as proproteins and that cellular levels of both mRNA and LMP-containing 20S proteasomes are differentially regulated.","date":"1993","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8365398","citation_count":61,"is_preprint":false},{"pmid":"14735146","id":"PMC_14735146","title":"Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1.","date":"2004","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14735146","citation_count":61,"is_preprint":false},{"pmid":"20174631","id":"PMC_20174631","title":"Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20174631","citation_count":55,"is_preprint":false},{"pmid":"7844523","id":"PMC_7844523","title":"Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene.","date":"1995","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/7844523","citation_count":53,"is_preprint":false},{"pmid":"24257606","id":"PMC_24257606","title":"Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/24257606","citation_count":53,"is_preprint":false},{"pmid":"16487046","id":"PMC_16487046","title":"LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins.","date":"2006","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/16487046","citation_count":52,"is_preprint":false},{"pmid":"16512786","id":"PMC_16512786","title":"Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16512786","citation_count":47,"is_preprint":false},{"pmid":"20153157","id":"PMC_20153157","title":"PSMB8 (LMP7) but not PSMB9 (LMP2) gene polymorphisms are associated to pigeon breeder's hypersensitivity pneumonitis.","date":"2010","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20153157","citation_count":44,"is_preprint":false},{"pmid":"16414974","id":"PMC_16414974","title":"Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders.","date":"2006","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16414974","citation_count":44,"is_preprint":false},{"pmid":"37433777","id":"PMC_37433777","title":"Immunoproteasome-specific subunit PSMB9 induction is required to regulate cellular proteostasis upon mitochondrial dysfunction.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37433777","citation_count":42,"is_preprint":false},{"pmid":"27477649","id":"PMC_27477649","title":"The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up.","date":"2016","source":"Chemical & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/27477649","citation_count":42,"is_preprint":false},{"pmid":"27926486","id":"PMC_27926486","title":"Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27926486","citation_count":41,"is_preprint":false},{"pmid":"7763114","id":"PMC_7763114","title":"Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis.","date":"1995","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/7763114","citation_count":41,"is_preprint":false},{"pmid":"24619410","id":"PMC_24619410","title":"IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24619410","citation_count":39,"is_preprint":false},{"pmid":"10764778","id":"PMC_10764778","title":"Adenovirus E1A down-regulates LMP2 transcription by interfering with the binding of stat1 to IRF1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10764778","citation_count":38,"is_preprint":false},{"pmid":"8056044","id":"PMC_8056044","title":"Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8056044","citation_count":38,"is_preprint":false},{"pmid":"33727065","id":"PMC_33727065","title":"Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.","date":"2021","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33727065","citation_count":36,"is_preprint":false},{"pmid":"8803612","id":"PMC_8803612","title":"Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines.","date":"1996","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/8803612","citation_count":36,"is_preprint":false},{"pmid":"36618068","id":"PMC_36618068","title":"A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma.","date":"2023","source":"Nano research","url":"https://pubmed.ncbi.nlm.nih.gov/36618068","citation_count":34,"is_preprint":false},{"pmid":"25864917","id":"PMC_25864917","title":"Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.","date":"2015","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25864917","citation_count":34,"is_preprint":false},{"pmid":"16474838","id":"PMC_16474838","title":"The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16474838","citation_count":33,"is_preprint":false},{"pmid":"10648037","id":"PMC_10648037","title":"LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis.","date":"2000","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/10648037","citation_count":32,"is_preprint":false},{"pmid":"9306872","id":"PMC_9306872","title":"The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis.","date":"1997","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/9306872","citation_count":32,"is_preprint":false},{"pmid":"15547699","id":"PMC_15547699","title":"Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15547699","citation_count":32,"is_preprint":false},{"pmid":"17142736","id":"PMC_17142736","title":"Heat shock up-regulates lmp2 and lmp7 and enhances presentation of immunoproteasome-dependent epitopes.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17142736","citation_count":31,"is_preprint":false},{"pmid":"7681985","id":"PMC_7681985","title":"Molecular basis of genetic polymorphism in major histocompatibility complex-linked proteasome gene (Lmp-2).","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7681985","citation_count":31,"is_preprint":false},{"pmid":"16606340","id":"PMC_16606340","title":"A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms.","date":"2006","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16606340","citation_count":31,"is_preprint":false},{"pmid":"16944024","id":"PMC_16944024","title":"Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice.","date":"2006","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16944024","citation_count":30,"is_preprint":false},{"pmid":"16222703","id":"PMC_16222703","title":"Proteasome subunit LMP2 is required for matrix metalloproteinase-2 and -9 expression and activities in human invasive extravillous trophoblast cell line.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16222703","citation_count":29,"is_preprint":false},{"pmid":"26713607","id":"PMC_26713607","title":"The role of PSMB9 upregulated by interferon signature in the pathophysiology of cutaneous lesions of dermatomyositis and systemic lupus erythematosus.","date":"2016","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26713607","citation_count":29,"is_preprint":false},{"pmid":"9000709","id":"PMC_9000709","title":"No independent associations of LMP2 and LMP7 polymorphisms with susceptibility to develop IDDM.","date":"1997","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/9000709","citation_count":29,"is_preprint":false},{"pmid":"9300732","id":"PMC_9300732","title":"Reduced expression of Tap1 and Lmp2 antigen-processing genes in the nonobese diabetic (NOD) mouse due to a mutation in their shared bidirectional promoter.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9300732","citation_count":29,"is_preprint":false},{"pmid":"7768065","id":"PMC_7768065","title":"Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis.","date":"1995","source":"Clinical and investigative medicine. Medecine clinique et experimentale","url":"https://pubmed.ncbi.nlm.nih.gov/7768065","citation_count":29,"is_preprint":false},{"pmid":"22355695","id":"PMC_22355695","title":"Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.","date":"2011","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/22355695","citation_count":28,"is_preprint":false},{"pmid":"7901128","id":"PMC_7901128","title":"Genomic organization of the mouse Lmp-2 gene and characteristic structure of its promoter.","date":"1993","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7901128","citation_count":28,"is_preprint":false},{"pmid":"7829535","id":"PMC_7829535","title":"Major histocompatibility-encoded human proteasome LMP2. Genomic organization and a new form of mRNA.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7829535","citation_count":26,"is_preprint":false},{"pmid":"9218589","id":"PMC_9218589","title":"Evolution of proteasome subunits delta and LMP2: complementary DNA cloning and linkage analysis with MHC in lower vertebrates.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9218589","citation_count":26,"is_preprint":false},{"pmid":"37679769","id":"PMC_37679769","title":"LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion.","date":"2023","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37679769","citation_count":25,"is_preprint":false},{"pmid":"8730138","id":"PMC_8730138","title":"Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis.","date":"1996","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/8730138","citation_count":24,"is_preprint":false},{"pmid":"9001385","id":"PMC_9001385","title":"The MHC-encoded TAP1/LMP2 bidirectional promoter is down-regulated in highly oncogenic adenovirus type 12 transformed cells.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9001385","citation_count":24,"is_preprint":false},{"pmid":"10468973","id":"PMC_10468973","title":"Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA1*0501.","date":"1999","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10468973","citation_count":24,"is_preprint":false},{"pmid":"15284441","id":"PMC_15284441","title":"Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15284441","citation_count":23,"is_preprint":false},{"pmid":"12883363","id":"PMC_12883363","title":"Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression.","date":"2003","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/12883363","citation_count":23,"is_preprint":false},{"pmid":"8672125","id":"PMC_8672125","title":"Molecular analysis of a recombinational hotspot adjacent to Lmp2 gene in the mouse MHC: fine location and chromatin structure.","date":"1996","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/8672125","citation_count":23,"is_preprint":false},{"pmid":"36746983","id":"PMC_36746983","title":"Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36746983","citation_count":22,"is_preprint":false},{"pmid":"8325639","id":"PMC_8325639","title":"Genomic organization and tissue expression of mouse proteasome gene Lmp-2.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8325639","citation_count":22,"is_preprint":false},{"pmid":"11169961","id":"PMC_11169961","title":"Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11169961","citation_count":22,"is_preprint":false},{"pmid":"10458773","id":"PMC_10458773","title":"Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10458773","citation_count":22,"is_preprint":false},{"pmid":"9348140","id":"PMC_9348140","title":"Polymorphism of the LMP2 gene and disease phenotype in ankylosing spondylitis: no association with disease severity.","date":"1997","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/9348140","citation_count":21,"is_preprint":false},{"pmid":"37944578","id":"PMC_37944578","title":"Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37944578","citation_count":20,"is_preprint":false},{"pmid":"12209365","id":"PMC_12209365","title":"LMP2 and LMP7 gene polymorphism in Mexican populations: Mestizos and Amerindians.","date":"2002","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12209365","citation_count":20,"is_preprint":false},{"pmid":"8854085","id":"PMC_8854085","title":"Molecular and serological analysis of polymorphisms in the murine major histocompatibility complex-encoded proteasome subunits, LMP-2 and LMP-7.","date":"1996","source":"Experimental and clinical immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8854085","citation_count":20,"is_preprint":false},{"pmid":"8575819","id":"PMC_8575819","title":"Genomic organization of a mouse MHC class II region including the H2-M and Lmp2 loci.","date":"1996","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8575819","citation_count":19,"is_preprint":false},{"pmid":"26171060","id":"PMC_26171060","title":"Association between LMP2 and LMP7 gene polymorphisms and the risk of gastric cancer: A case-control study.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26171060","citation_count":18,"is_preprint":false},{"pmid":"16842756","id":"PMC_16842756","title":"In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16842756","citation_count":18,"is_preprint":false},{"pmid":"36045515","id":"PMC_36045515","title":"Identification of PSMB9 and CXCL13 as Immune-related Diagnostic Markers for Rheumatoid Arthritis by Machine Learning.","date":"2022","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/36045515","citation_count":17,"is_preprint":false},{"pmid":"9170499","id":"PMC_9170499","title":"In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).","date":"1997","source":"Archives of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9170499","citation_count":17,"is_preprint":false},{"pmid":"34257379","id":"PMC_34257379","title":"Identification and characterization of a novel Epstein-Barr Virus-encoded circular RNA from LMP-2 Gene.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34257379","citation_count":16,"is_preprint":false},{"pmid":"33771238","id":"PMC_33771238","title":"LMP2-DC Vaccine Elicits Specific EBV-LMP2 Response to Effectively Improve Immunotherapy in Patients with Nasopharyngeal Cancer.","date":"2020","source":"Biomedical and environmental sciences : BES","url":"https://pubmed.ncbi.nlm.nih.gov/33771238","citation_count":16,"is_preprint":false},{"pmid":"33968021","id":"PMC_33968021","title":"The Immunoproteasome Subunits LMP2, LMP7 and MECL-1 Are Crucial Along the Induction of Cerebral Toxoplasmosis.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33968021","citation_count":16,"is_preprint":false},{"pmid":"21741845","id":"PMC_21741845","title":"A bright approach to the immunoproteasome: development of LMP2/β1i-specific imaging probes.","date":"2011","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21741845","citation_count":16,"is_preprint":false},{"pmid":"10811990","id":"PMC_10811990","title":"The expression of MHC class I, TAP1/2, and LMP2/7 gene in human gastric cancer cell lines.","date":"2000","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10811990","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51135,"output_tokens":7614,"usd":0.133807,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16994,"output_tokens":6776,"usd":0.127185,"stage2_stop_reason":"end_turn"},"total_usd":0.260992,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"LMP2 (PSMB9) incorporation into 20S proteasomes alters peptidase activities: it reduces cleavage after acidic residues and increases hydrolysis after basic residues, without affecting hydrophobic activity. These changes are proportional to the amount of LMP2 incorporated and can account for the IFN-γ-induced shift in proteasome activity that favors generation of peptides with hydrophobic or basic C-termini for MHC class I presentation.\",\n      \"method\": \"Gene transfection of LMP2 into lymphoblasts or HeLa cells followed by in vitro peptidase activity assays on purified 20S and 26S proteasomes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with transfection, dose-response relationship established, replicated across cell types\",\n      \"pmids\": [\"7937744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"LMP2-deficient mice have proteasomes with altered peptidase activities and antigen-presenting cells show reduced capacity to stimulate a T cell hybridoma specific for an H-2Db-restricted influenza nucleoprotein epitope. LMP2-/- mice also have ~60-70% of wild-type CD8+ T lymphocyte levels and generate 5- to 6-fold fewer influenza nucleoprotein-specific CTL precursors, indicating LMP2 influences antigen processing in vivo.\",\n      \"method\": \"Gene targeting (LMP2 knockout mice), purified proteasome peptidase assays, T cell hybridoma stimulation assay, CTL precursor frequency measurement\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple orthogonal phenotypic readouts (biochemical + cellular + immunological), replicated in vivo\",\n      \"pmids\": [\"7600282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Incorporation of MECL-1 into the 20S proteasome is directly dependent on LMP2 (PSMB9) expression but independent of LMP7. Conversely, LMP2 uptake into proteasomes is strongly enhanced by MECL-1 co-expression. LMP2 and MECL-1 are mutually required for incorporation at the level of proteasome precursor formation, ensuring concerted assembly of two IFN-γ-inducible subunits.\",\n      \"method\": \"Co-transfection experiments with LMP2 and MECL-1 expression constructs, analysis of proteasome subunit composition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct co-expression experiments with gain/loss of each partner, mechanistically well-defined, replicated with multiple combinations\",\n      \"pmids\": [\"9256419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"LMP2 (PSMB9) and LMP7 are synthesized as proproteins (~24 kDa and ~30 kDa respectively) and are processed within 13-16S proteasome precursor complexes; only their processed forms are incorporated into active 20S proteasomes.\",\n      \"method\": \"Pulse-chase experiments in mouse T cells, biochemical fractionation and analysis of 13-16S precursor complexes vs. mature 20S proteasomes\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with pulse-chase, direct demonstration of proprotein processing within precursor complexes\",\n      \"pmids\": [\"8120905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"LMP2+ proteasomes are specifically required for MHC class I-restricted presentation of influenza virus antigens. A T cell lymphoma (SP3) deficient only in LMP2 (among MHC-encoded antigen presentation genes) fails to present influenza antigens. Restoration of LMP2 expression (via IFN-γ transfection) rescues antigen presentation; antisense-LMP2 mRNA in IFN-γ-transfected SP3 cells or in LMP2-expressing L929 fibroblasts selectively represses presentation of the same antigens.\",\n      \"method\": \"Antisense RNA expression, IFN-γ gene transfection, CTL assays, analysis of selective LMP2 deficiency in SP3 lymphoma cells\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain- and loss-of-function with antisense in two cell lines, specific antigen presentation phenotype, selective LMP2 requirement established\",\n      \"pmids\": [\"7583150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The PA28 (11S regulator) and LMP2/LMP7 subunits act together to govern peptide product profiles of 20S proteasomes in vitro. Incorporation of LMP2 and/or LMP7 changes cleavage site preference and peptide product quality from a 25-mer substrate. The 11S regulator does not preferentially activate LMP2- or LMP7-containing proteasomes but markedly changes both the quality and quantity of peptides produced when bound to any proteasome preparation.\",\n      \"method\": \"In vitro digestion of a 25-mer peptide substrate with purified 20S proteasomes from LMP transfectants ± purified PA28, product analysis by HPLC and electrospray mass spectrometry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro enzymatic assay with mass spectrometric product identification, multiple proteasome compositions tested\",\n      \"pmids\": [\"7559557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Incorporation of LMP2 (alone or with LMP7) into 20S proteasomes changes subunit stoichiometry, alters cleavage site preference, and changes the quality of peptides processed from a murine cytomegalovirus IE pp89 25-mer polypeptide substrate, independent of IFN-γ. Both LMP subunits together also induce a drastic increase in positive cooperativity (Hill coefficient) between proteasome subunits.\",\n      \"method\": \"IFN-γ-independent LMP transfection into murine fibroblasts, in vitro dual-cleavage digestion assays with purified 20S proteasomes, fluorogenic peptide substrate assays (Vmax, S0.5, Hill coefficient)\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with multiple substrates and kinetic parameters measured\",\n      \"pmids\": [\"7589133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"LMP2 (PSMB9) and the constitutive subunit Y (delta) have opposing effects on proteasome peptidase activities: Y promotes cleavage after acidic residues while LMP2 suppresses it. Upon IFN-γ treatment, LMP2 replaces Y, thereby suppressing postacidic cleavage. Loss of Y by LMP2 incorporation accounts for suppression of postacidic cleavages, and loss of X contributes to increased hydrolysis after hydrophobic and basic residues.\",\n      \"method\": \"Transfection of X and Y subunit cDNAs into HeLa cells, peptidase activity assays, proteasome subunit composition analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assays with gain-of-function transfection, mechanistic subunit replacement model established\",\n      \"pmids\": [\"8663318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human TAP1 and LMP2 genes are divergently transcribed from a shared bidirectional promoter of only 593 bp. The NF-κB element proximal to the TAP1 gene controls TNF-α induction of both TAP1 and LMP2; an adjacent GC box is required for basal expression of both genes and augments TNF-α induction. In vivo footprinting confirmed protein-DNA interactions at these sites; in vitro binding confirmed p50/p65 and p52/p65 heterodimers bind the NF-κB site, and Sp1 binds the GC box.\",\n      \"method\": \"Bidirectional reporter assays, site-specific mutagenesis, in vivo genomic footprinting, in vitro DNA-binding studies\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — promoter mutagenesis, reporter assays, and in vivo/in vitro footprinting all converge on same regulatory elements\",\n      \"pmids\": [\"7699330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"IRF-1 is required for IFN-γ up-regulation of both TAP1 and LMP2. In vivo footprinting shows IFN-γ increases protein-DNA contacts at an IRF-E element essential for up-regulation of both genes; gel shift analysis shows this site binds IRF-1. In IRF-1-deficient mice, TAP1 and LMP2 expression are both greatly reduced, surface class I MHC is reduced, and CD8+ T cells are reduced.\",\n      \"method\": \"In vivo footprinting, gel shift (EMSA), analysis of IRF-1-/- mice (KO phenotype), surface MHC and CD8 T cell measurement\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with multiple cellular phenotypes, confirmed by molecular footprinting and EMSA\",\n      \"pmids\": [\"8885869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Adenovirus E1A down-regulates LMP2 transcription by binding to Stat1 and interfering with the formation of the constitutive Stat1-IRF1 complex that normally occupies the overlapping ICS-2/GAS element of the LMP2 promoter. E1A sequesters IRF1 by occupying IRF1-binding domains on Stat1. The mutant E1A protein RG2 (binds Stat1 but not CBP/p300) also represses LMP2, while Delta2-36 (binds neither) does not, establishing that Stat1-binding is the key mechanism.\",\n      \"method\": \"E1A mutant analysis, EMSA/gel shift showing Stat1-IRF1 complex formation, reporter assays, protein-protein interaction studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — structure-function mutagenesis of E1A, EMSA for complex disruption, mechanistic dissection with multiple E1A mutants\",\n      \"pmids\": [\"10764778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"LMP2 (PSMB9) is synthesized as a proprotein of 24 kDa; pulse-chase experiments demonstrate that the LMP2 polypeptide undergoes post-translational processing (from ~22.3 kDa to ~21.5 kDa) when incorporated into proteasomes. Two mRNA forms exist (LMP2.1 and LMP2.s resulting from alternative splicing of 30 bp from the first exon), yet both encode proteins processed to the same final size in proteasomes.\",\n      \"method\": \"Pulse-chase experiments, immunoblot with anti-recombinant LMP2.s antibodies, RT-PCR/cDNA sequence analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pulse-chase biochemistry plus sequence analysis, single lab\",\n      \"pmids\": [\"7829535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Overexpression of all three immunoproteasome subunits (LMP2, LMP7, and MECL-1) together markedly enhances MHC class I presentation of the immunodominant LCMV NP118 epitope. In vitro, immunoproteasomes generate higher amounts of 11- and 12-mer precursor fragments containing NP118, consistent with cytosolic precursor generation for TAP transport. PA28 overexpression does not have a comparable effect on this epitope.\",\n      \"method\": \"Triple transfection of LMP2/LMP7/MECL-1, CTL presentation assays, in vitro digestion of substrate with HPLC product analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with defined substrates and product identification combined with cell-based presentation assays\",\n      \"pmids\": [\"10878350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LMP2-/- mice have reduced proteasome activities (chymotryptic, tryptic, and caspase-like) in both brain and liver, accompanied by increased levels of oxidatively damaged proteins in both tissues. This demonstrates that individual proteasome subunit (LMP2) expression regulates overall proteasome activity and protein oxidation in vivo.\",\n      \"method\": \"LMP2 knockout mice, proteasome activity assays (fluorogenic substrates), protein oxidation measurement (carbonyl content) in brain and liver tissue\",\n      \"journal\": \"Antioxidants & redox signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with biochemical readout in two tissues, single lab\",\n      \"pmids\": [\"16487046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HIV-1 Tat protein represses LMP2 transcription by competing with STAT1 for binding to IRF-1 on the overlapping ICS-2/GAS element of the LMP2 promoter. The constitutive LMP2 basal transcription depends on an unphosphorylated STAT1-IRF-1 complex at this element; intracellular Tat sequesters IRF-1, impairing complex formation and reducing LMP2 expression, with a consequent increase in proteolytic activity.\",\n      \"method\": \"Reporter assays, EMSA/ChIP to demonstrate STAT1-IRF-1 complex disruption by Tat, Western blot for LMP2 protein levels, proteasome activity assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA for molecular mechanism combined with functional reporter and activity assays, single lab\",\n      \"pmids\": [\"16512786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IFN-γ controls IL-33 protein levels through STAT1 and the LMP2 proteasome subunit. IFN-γ elevates LMP2 levels; siRNA-mediated silencing of LMP2 abrogates the IFN-γ-induced down-regulation of IL-33 protein, indicating LMP2 mediates non-canonical (non-antigen presentation) proteolysis of IL-33 in a caspase-independent fashion in pulmonary fibroblasts.\",\n      \"method\": \"siRNA knockdown of LMP2 and STAT1, pharmacological inhibition, adenoviral dual gene delivery, Western blot for IL-33 protein levels in vitro and in vivo\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with rescue experiments, in vivo confirmation, single lab\",\n      \"pmids\": [\"24619410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LMP2 siRNA knockdown in the human invasive extravillous trophoblast cell line (HTR8/Svneo) suppresses MMP-2 and MMP-9 mRNA expression and activities. LMP2 contributes to IκBα degradation and p50 NF-κB subunit generation; inhibition of LMP2 reduces nuclear translocation of active NF-κB heterodimers, thereby reducing MMP-2 and MMP-9 expression.\",\n      \"method\": \"siRNA transfection, RT-PCR for MMP-2/9, gelatin zymography for MMP activity, Western blot for IκBα, p50, p65 in cytosolic and nuclear fractions, NF-κB inhibitor (SN50) control\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with multiple orthogonal readouts (mRNA, activity, protein fractionation), single lab\",\n      \"pmids\": [\"16222703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LMP2-/- mice have mixed (hybrid) proteasomes in immune cells containing both standard and immunosubunits, and this compromises antiviral antibody responses, splenic B cell numbers, adoptively transferred B cell survival and function, Th cell function, and dendritic cell secretion of IL-6, TNF-α, IL-1β, and type I IFNs. These defects are associated with altered NF-κB activity rather than compromised overall protein degradation.\",\n      \"method\": \"LMP2 knockout mice, adoptive transfer experiments, cytokine measurements by ELISA, NF-κB activity assays, flow cytometry for immune cell populations\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with multiple immune readouts and mechanistic linkage to NF-κB, single lab\",\n      \"pmids\": [\"20228196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Co-inhibition of LMP2 (β1i/PSMB9) and LMP7 (β5i) is required to block autoimmunity. Selective LMP7-only inhibition with PRN1126 has limited effects on IL-6 secretion, experimental colitis, and EAE. Prolonged ONX 0914 exposure inhibits both LMP7 and LMP2. Combined LMP7+LMP2 inhibition impairs MHC class I surface expression, IL-6 secretion, Th17 differentiation, and strongly ameliorates disease in colitis and EAE models.\",\n      \"method\": \"Selective inhibitors (PRN1126, LU-001i, ML604440, ONX 0914), cytokine assays (IL-6), flow cytometry for MHC I and Th17 cells, in vivo colitis and EAE models\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with selective inhibitors in vitro and in vivo, multiple disease models, single lab\",\n      \"pmids\": [\"30279279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A de novo PSMB9 p.G156D mutation causes a novel type I interferonopathy. Patient-derived B lymphoblastoid cell lines show reduced proteasome activities; exogenous transduction of mutant PSMB9 p.G156D into normal LCLs significantly suppresses proteasome activities and eliminates endogenous PSMB9 protein along with reduction of other immunoproteasome subunits PSMB8 and PSMB10, demonstrating a dominant-negative mechanism with co-subunit destabilization.\",\n      \"method\": \"Whole-exome sequencing, patient-derived LCL proteasome activity assays, lentiviral transduction of mutant PSMB9 into normal LCLs, Western blot for immunoproteasome subunit levels\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient mutation validated by transduction into normal cells with biochemical readout, single lab\",\n      \"pmids\": [\"33727065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In human cells, mitochondrial dysfunction leads to upregulation of the immunoproteasome-specific subunit PSMB9 as a proteostasis defense response. PSMB9 expression under mitochondrial stress is dependent on the translation elongation factor EEF1A2. This defines a mode of proteasomal activation through change in proteasome composition driven by EEF1A2 and its spatial regulation.\",\n      \"method\": \"Mitochondrial dysfunction models in human cells, proteomics, siRNA knockdown of EEF1A2, Western blot for PSMB9 and other proteasome subunits, proteasome activity assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-method study (proteomics, siRNA, activity assays) in human cells, single lab\",\n      \"pmids\": [\"37433777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LMP2 (PSMB9) inhibition ameliorates ischemia/hypoxia-induced blood-brain barrier injury through activation of the Wnt/β-catenin signaling pathway. LMP2 knockdown in rat MCAO/reperfusion model restores tight junction proteins (occludin, claudin-1, ZO-1), increases microvascular density, and decreases BBB permeability. Co-silencing of β-catenin partially counteracted benefits of LMP2 silencing, establishing LMP2's pathway position upstream of Wnt/β-catenin.\",\n      \"method\": \"Lentivirus-mediated LMP2 shRNA in MCAO/R rat model, siRNA in OGD/R cell model, co-transfection with β-catenin siRNA, Western blot, Evans blue permeability assay, immunofluorescence\",\n      \"journal\": \"Military Medical Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo shRNA + in vitro siRNA with epistasis (β-catenin co-KD), multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"34857032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PSMB9 (LMP2) knockdown in keratinocytes leads to significant suppression of TGF-β2 and TGF-β3, which are inducers of versican synthesis. IFN-γ stimulates PSMB9 expression in cultured keratinocytes. This places PSMB9 upstream of TGF-β2/β3 in the pathway regulating versican-mediated extracellular matrix composition in skin.\",\n      \"method\": \"siRNA knockdown of PSMB9 in keratinocytes, RT-PCR/Western blot for TGF-β2, TGF-β3, versican; IFN stimulation assays; proteomics of DM vs. healthy skin\",\n      \"journal\": \"The British journal of dermatology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — siRNA KD with mRNA readout, single method for the mechanistic claim, single lab\",\n      \"pmids\": [\"26713607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Structure-based design identified β1i (PSMB9/LMP2)-selective inhibitors using X-ray structures of murine constitutive and immunoproteasome 20S core particles as templates. Cell-permeable compounds with selectivity for β1i over β5i and over constitutive β1c were developed, confirming that the PSMB9 active site has structural features distinct from other proteasome catalytic subunits.\",\n      \"method\": \"Structure-based drug design using X-ray crystal structures of 20S proteasome, synthesis and biochemical testing of inhibitors for selectivity and potency against individual subunits\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-guided design validated by biochemical selectivity assays; structural data from murine not human proteasome\",\n      \"pmids\": [\"25006746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LMP2-specific irreversible small molecule inhibitors selectively modify the LMP2/β1i subunit of the immunoproteasome with high specificity. LMP2-rich cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor compared to LMP2-deficient cancer cells, implicating LMP2 catalytic activity in regulating cell growth of tumors that highly express it.\",\n      \"method\": \"Activity-based labeling with LMP2-selective inhibitors, cell viability assays comparing LMP2-expressing vs. LMP2-deficient cancer cell lines\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — activity-based chemical probe with selectivity demonstrated, functional growth assay comparing isogenic LMP2+/- cells, single lab\",\n      \"pmids\": [\"17462577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Heat shock transcriptionally up-regulates lmp2 and lmp7 in mouse and human cells, and heat-shocked cells show enhanced presentation of immunoproteasome-dependent MHC class I epitopes (LCMV NP118-126, adenovirus E1B192-200) but not immunoproteasome-independent epitopes, demonstrating that heat shock-driven LMP2 induction functionally alters antigen processing.\",\n      \"method\": \"RT-PCR for lmp2/lmp7 mRNA after heat shock, CTL presentation assays for immunoproteasome-dependent vs. -independent epitopes\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional induction linked to functional presentation change with epitope-specificity controls, single lab\",\n      \"pmids\": [\"17142736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In the NOD mouse, a T→A mutation in the shared bidirectional promoter of Lmp2 and Tap1 eliminates an initiator (Inr) element in the Lmp2 orientation, reduces Lmp2 and Tap1 mRNA levels, eliminates a Lmp2 transcription start site, and reduces proteasome peptide substrate activity. This promoter mutation thus reduces both Lmp2 and Tap1 gene expression.\",\n      \"method\": \"Sequencing of NOD vs. Balb/c promoter, Northern blot, 5'-RACE, luciferase reporter assays with NOD promoter construct, proteasome activity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutation identified and functionally confirmed by reporter and activity assays, multiple methods, single lab\",\n      \"pmids\": [\"9300732\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PSMB9 (LMP2/β1i) is an IFN-γ-inducible catalytic beta subunit of the immunoproteasome that is synthesized as a proprotein, processed within 13-16S precursor complexes, and incorporated into 20S proteasomes where it replaces the constitutive delta/Y subunit; its incorporation suppresses cleavage after acidic residues and enhances cleavage after basic residues, shifting peptide product profiles toward ligands suitable for MHC class I loading, and requires mutual co-incorporation with MECL-1; LMP2 expression is coordinately regulated with TAP1 from a shared bidirectional promoter via IRF-1, STAT1, NF-κB and Sp1, and is subject to repression by viral proteins (adenovirus E1A, HIV-1 Tat) that disrupt the constitutive STAT1-IRF-1 complex; beyond antigen presentation, LMP2 regulates NF-κB-dependent gene expression (including MMP-2/9), controls IL-33 proteolysis, influences Wnt/β-catenin signaling in endothelial cells under ischemia, and is induced during mitochondrial stress in an EEF1A2-dependent manner to preserve proteostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PSMB9 (LMP2/β1i) is an IFN-γ-inducible catalytic β subunit of the immunoproteasome that reshapes proteasomal peptide output to favor MHC class I antigen presentation [#0, #4]. Synthesized as a ~24 kDa proprotein, it is processed within 13-16S precursor complexes and only the mature form is incorporated into 20S proteasomes [#3, #11]. Upon incorporation it replaces the constitutive Y/δ subunit, suppressing cleavage after acidic residues while enhancing hydrolysis after basic residues in a dose-dependent manner; these opposing activities of Y and LMP2 account for the IFN-γ-induced shift in proteasome specificity [#0, #7]. Its assembly into the 20S particle is mutually co-dependent with MECL-1, ensuring concerted incorporation of two immunosubunits at the precursor stage [#2]. Functionally, LMP2-containing proteasomes are selectively required to generate cytosolic precursor fragments for defined viral epitopes, and LMP2-deficient mice show reduced CD8+ T cell numbers and impaired CTL generation against influenza nucleoprotein [#1, #4, #12]. PSMB9 expression is coordinately regulated with TAP1 from a shared 593 bp bidirectional promoter, driven by IRF-1, a constitutive STAT1-IRF-1 complex, NF-κB (p50/p65), and Sp1, and is repressed by viral proteins (adenovirus E1A, HIV-1 Tat) that disrupt the STAT1-IRF-1 complex at the overlapping ICS-2/GAS element [#8, #9, #10, #14]. Beyond antigen processing, PSMB9 supports broader proteostasis, controlling overall proteasome activity and limiting protein oxidation in vivo [#13], modulating NF-κB-dependent gene expression including MMP-2/9 [#16], mediating non-canonical IL-33 proteolysis [#15], and being induced as a proteostasis defense during mitochondrial stress in an EEF1A2-dependent manner [#20]. A de novo PSMB9 p.G156D mutation causes a type I interferonopathy through a dominant-negative mechanism that destabilizes co-subunits PSMB8 and PSMB10 [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that LMP2 is a catalytic immunoproteasome subunit whose incorporation directly rewires proteasome cleavage specificity toward MHC class I-suitable peptides, rather than being merely a passive structural component.\",\n      \"evidence\": \"LMP2 transfection into lymphoblasts/HeLa cells with in vitro peptidase assays on purified 20S/26S proteasomes\",\n      \"pmids\": [\"7937744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the in vivo consequence for antigen presentation\", \"Did not resolve the structural basis of the cleavage shift\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Showed that LMP2 is made as a 24 kDa proprotein and post-translationally processed during proteasome incorporation, defining a maturation requirement for catalytic activity.\",\n      \"evidence\": \"Pulse-chase and immunoblot in mouse T cells with cDNA/splice-form analysis\",\n      \"pmids\": [\"7829535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the processing protease\", \"Functional role of the two splice forms unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined where processing occurs by showing LMP2 propeptide maturation happens within 13-16S precursor complexes and only mature forms enter active 20S particles.\",\n      \"evidence\": \"Pulse-chase and biochemical fractionation of precursor vs. mature complexes in mouse T cells\",\n      \"pmids\": [\"8120905\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Assembly chaperones not identified\", \"Order of subunit recruitment within precursors not fully resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Linked LMP2 biochemistry to immune function in vivo, demonstrating that LMP2 loss alters proteasome activity and reduces CD8+ T cell numbers and antigen-specific CTL precursor generation.\",\n      \"evidence\": \"LMP2 knockout mice with proteasome assays, T cell hybridoma stimulation, and CTL precursor frequency\",\n      \"pmids\": [\"7600282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate effects on proteasome activity from effects on T cell development\", \"Specific epitope dependence not yet mapped\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Confirmed selective LMP2 dependence of antigen presentation using gain- and loss-of-function in cells, showing LMP2 is specifically required for presentation of defined viral antigens.\",\n      \"evidence\": \"Antisense LMP2 RNA, IFN-γ transfection, and CTL assays in SP3 lymphoma and L929 fibroblasts\",\n      \"pmids\": [\"7583150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality across diverse epitopes not established\", \"Did not address contribution of other immunosubunits\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Resolved how LMP2 cooperates with regulators and other subunits, showing LMP2/LMP7 set cleavage-site preference while PA28/11S independently boosts peptide quality and quantity.\",\n      \"evidence\": \"In vitro digestion of 25-mer substrates with purified LMP-transfectant 20S ± PA28, HPLC/MS product analysis; IFN-γ-independent transfection with kinetic measurements\",\n      \"pmids\": [\"7559557\", \"7589133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate-specificity rules for endogenous antigens not generalized\", \"Cooperativity mechanism between subunits not structurally defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Pinpointed the molecular basis of the cleavage shift to subunit replacement, showing LMP2 and constitutive Y have opposing effects and LMP2 substitution suppresses postacidic cleavage.\",\n      \"evidence\": \"Transfection of X/Y subunit cDNAs into HeLa cells with peptidase and composition analyses\",\n      \"pmids\": [\"8663318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic basis of substrate specificity difference not resolved\", \"Contribution of X loss not fully separated from Y loss\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Established a co-assembly rule whereby LMP2 and MECL-1 are mutually required for incorporation at the precursor stage, independent of LMP7.\",\n      \"evidence\": \"Co-transfection of LMP2 and MECL-1 with proteasome subunit composition analysis\",\n      \"pmids\": [\"9256419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular signal coordinating their co-incorporation not identified\", \"Stoichiometry of mixed/hybrid proteasomes not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the transcriptional architecture of PSMB9, showing TAP1 and LMP2 share a compact bidirectional promoter with NF-κB-driven cytokine induction and an Sp1/GC box for basal expression.\",\n      \"evidence\": \"Bidirectional reporters, mutagenesis, in vivo footprinting, and in vitro NF-κB/Sp1 DNA-binding studies\",\n      \"pmids\": [\"7699330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address IFN-γ-specific elements\", \"Cell-type-specific regulation not explored\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identified IRF-1 as the IFN-γ-responsive transcription factor required for coordinate TAP1/LMP2 upregulation, linking promoter occupancy to MHC class I surface expression and CD8+ T cell numbers.\",\n      \"evidence\": \"In vivo footprinting, EMSA, and IRF-1-deficient mice with MHC and CD8 readouts\",\n      \"pmids\": [\"8885869\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with STAT1 at the same element not yet dissected\", \"Did not separate direct vs. indirect IRF-1 effects\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Connected promoter variation to disease susceptibility, showing a NOD-mouse promoter mutation ablates an Inr element and reduces both Lmp2 and Tap1 expression and proteasome activity.\",\n      \"evidence\": \"Sequencing, Northern blot, 5'-RACE, luciferase reporters, and proteasome activity assays of NOD vs. control promoters\",\n      \"pmids\": [\"9300732\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link to autoimmune phenotype not directly demonstrated\", \"Effect specific to mouse strain context\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed viral subversion of PSMB9 by demonstrating adenovirus E1A represses LMP2 transcription by sequestering IRF1 via STAT1 binding, disrupting the constitutive STAT1-IRF1 complex.\",\n      \"evidence\": \"E1A structure-function mutants, EMSA for complex disruption, and reporter assays\",\n      \"pmids\": [\"10764778\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify downstream impact on antigen presentation in infected cells\", \"Other viral repressors not addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated combinatorial enhancement of presentation, showing co-overexpression of LMP2/LMP7/MECL-1 markedly boosts presentation of an immunodominant epitope by generating more cytosolic precursor fragments.\",\n      \"evidence\": \"Triple transfection with CTL assays and in vitro substrate digestion/HPLC analysis\",\n      \"pmids\": [\"10878350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each subunit not separated\", \"Did not generalize beyond the tested epitope\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Extended PSMB9 function to global proteostasis, showing LMP2 loss reduces multiple proteasome activities and increases oxidative protein damage in non-immune tissues.\",\n      \"evidence\": \"LMP2 knockout mice with fluorogenic activity assays and protein carbonyl measurements in brain and liver\",\n      \"pmids\": [\"16487046\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking subunit loss to global activity not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined an HIV-1 strategy paralleling E1A, with Tat repressing LMP2 by competing with STAT1 for IRF-1 at the ICS-2/GAS element.\",\n      \"evidence\": \"Reporter assays, EMSA/ChIP for STAT1-IRF-1 disruption, and proteasome activity assays\",\n      \"pmids\": [\"16512786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional impact on viral antigen presentation not quantified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Implicated PSMB9 in NF-κB-driven matrix remodeling, showing LMP2 knockdown reduces IκBα degradation, p50 generation, and MMP-2/9 expression in trophoblasts.\",\n      \"evidence\": \"siRNA with RT-PCR, gelatin zymography, and cytosolic/nuclear fractionation Western blots\",\n      \"pmids\": [\"16222703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrate of LMP2 in NF-κB activation not identified\", \"Single cell type\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked stress-induced LMP2 to functional changes in antigen processing, showing heat shock transcriptionally upregulates lmp2/lmp7 and selectively enhances immunoproteasome-dependent epitope presentation.\",\n      \"evidence\": \"RT-PCR after heat shock and CTL assays with dependent vs. independent epitope controls\",\n      \"pmids\": [\"17142736\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors mediating heat-shock induction not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided chemical-biology evidence that LMP2 catalytic activity has cell-intrinsic roles, with LMP2-selective irreversible inhibitors preferentially inhibiting growth of LMP2-rich cancer cells.\",\n      \"evidence\": \"Activity-based labeling with LMP2-selective probes and viability assays in LMP2+/- cancer lines\",\n      \"pmids\": [\"17462577\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrates mediating growth effect unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Refined the LMP2 phenotype mechanistically, showing immune defects in LMP2-/- mice track with altered NF-κB activity rather than impaired bulk protein degradation.\",\n      \"evidence\": \"LMP2 knockout mice with adoptive transfer, cytokine ELISAs, NF-κB activity assays, and flow cytometry\",\n      \"pmids\": [\"20228196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NF-κB substrate of immunoproteasome not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a non-antigen-presentation proteolytic role, showing IFN-γ downregulates IL-33 protein through STAT1 and LMP2 in a caspase-independent manner.\",\n      \"evidence\": \"siRNA knockdown of LMP2/STAT1, adenoviral delivery, and Western blot for IL-33 in vitro and in vivo\",\n      \"pmids\": [\"24619410\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect cleavage of IL-33 not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Confirmed PSMB9 has a structurally distinct active site by designing β1i-selective inhibitors using immunoproteasome crystal structures.\",\n      \"evidence\": \"Structure-based drug design from murine 20S X-ray structures with biochemical selectivity assays\",\n      \"pmids\": [\"25006746\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural data from murine, not human, proteasome\", \"Selectivity in cellular context not fully validated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established that dual LMP2+LMP7 inhibition is required for therapeutic immunomodulation, showing LMP7-only blockade is insufficient to suppress autoimmunity.\",\n      \"evidence\": \"Selective inhibitors with IL-6 assays, MHC I and Th17 flow cytometry, and colitis/EAE models\",\n      \"pmids\": [\"30279279\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative catalytic contribution of LMP2 vs. LMP7 not quantified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated PSMB9 causes human Mendelian disease, identifying a de novo p.G156D mutation that drives a type I interferonopathy through a dominant-negative mechanism destabilizing co-subunits.\",\n      \"evidence\": \"Whole-exome sequencing, patient LCL activity assays, and lentiviral transduction of mutant PSMB9 into normal LCLs with subunit Westerns\",\n      \"pmids\": [\"33727065\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking proteasome dysfunction to interferon activation not defined\", \"Single patient/lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed PSMB9 upstream of Wnt/β-catenin signaling in vascular pathology, showing LMP2 inhibition restores blood-brain barrier integrity after ischemia in a β-catenin-dependent manner.\",\n      \"evidence\": \"Lentiviral LMP2 shRNA in MCAO/R rats, OGD/R cell models, β-catenin co-silencing epistasis, and permeability/tight-junction readouts\",\n      \"pmids\": [\"34857032\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting LMP2 to Wnt/β-catenin not molecularly defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a mitochondrial-stress proteostasis role, showing PSMB9 is upregulated as a defense response in an EEF1A2-dependent manner under mitochondrial dysfunction.\",\n      \"evidence\": \"Mitochondrial dysfunction models in human cells with proteomics, EEF1A2 siRNA, and proteasome activity assays\",\n      \"pmids\": [\"37433777\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of EEF1A2-dependent PSMB9 induction not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How non-antigen-presentation roles of PSMB9 (NF-κB regulation, IL-33 and IL-33-like substrate proteolysis, Wnt/β-catenin and mitochondrial-stress signaling) are mechanistically connected to its catalytic specificity remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physiological substrates beyond MHC-precursor peptides not identified\", \"Human structural model of the PSMB9 active site not established\", \"Mechanism linking proteasome dysfunction to interferon hyperactivation unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 5, 6, 7, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 7, 13]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 4, 12, 17]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 3, 13, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 9, 10, 14]}\n    ],\n    \"complexes\": [\"immunoproteasome 20S core particle\", \"13-16S proteasome precursor complex\"],\n    \"partners\": [\"MECL-1\", \"PSMB8\", \"PSMB10\", \"TAP1\", \"IRF1\", \"STAT1\", \"EEF1A2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}